Global Oncology Drugs Market By Overview
Introduction:
Oncology is a condition in which body faces unrestricted growth of cells which spread to other parts also. Abnormal or damaged cells multiply & converted into lumps of tissues i.e. Tumor formation. Cancer drugs has crucial role in controlling the formation of malignant neoplasm. Various types of cancer drugs are available in the market based on product type, dosage form, specific type or stage of cancer etc. In the 1940s, one of the first drugs that was used clinically in modern medicine for the treatment of cancer was the alkylating agent mechlorethamine was found to be effective in treating lymphomas. Similarly, the antimetabolite methotrexate was the first medicine to treat a solid tumour in 1956. Since then many anticancer drugs have been developed and used with much success. Though, anticancer drugs are effective but generally it has toxic effect on normal human cells can cause numerous side effects, some of which are life-threatening. Oncology Drug market accounted for US$ 181.47 billion in 2020 and is estimated to be US$ 869.6 billion by 2030 and is anticipated to register a CAGR of 8.9%.
Impact of Covid-19 pandemic on market
Globally, the COVID-19 outbreak has had a favorable impact on this sector. In response to the COVID-19 emergency, several market segments have seen an increase in drug demand. Pharmaceutical businesses in this industry have greatly improved their supply chain management, increased their R&D skills, and increased their manufacturing management and quality control investments. This report will quantify the impact of this pandemic on the Oncology Drug market.
Global Oncology Drugs Market By Dynamics
Technological Advancement and Increased R&D activities in Oncology Drug Market
The market for oncology drug market is being driven by technological advancements & increased demand for R&D activities in cancer. Also, rising incidence of various types of malignancies, and growing concerns about high cancer-related death rates are some of the major factors affecting oncology drug market. For instance, in 2019, there were an estimated 23.6 million (95% UI, 22.2-24.9 million) new cancer cases (17.2 million when excluding nonmelanoma skin cancer) and 10.0 million (95% UI, 9.36-10.6 million) cancer deaths globally, with an estimated 250 million (235-264 million) DALYs(Disability Adjusted Life Years) due to cancer. Since 2010, these represented a 26.3% (95% UI, 20.3%-32.3%) increase in new cases, a 20.9% (95% UI, 14.2%-27.6%) increase in deaths, and a 16.0% (95% UI, 9.3%-22.8%) increase in DALYs. Above data represents the size & scope of the oncology market. In addition, the oncology drug market is likely to be driven by the launch of novel cancer drugs and therapies & its awareness in the society, government support to enhance healthcare conditions, personalized medicines, increase in the number of organizations’ collaborations and partnerships are projected to create new prospects for the global oncology drugs market.
High cost & Side-effects of Cancer drugs
Threat of failure & adverse effects related to cancer drugs therapies is predicted to restrain the expansion of the market. The high cost of cancer treatments, government’s restrictions, massive investment in therapy development and clinical trials are some of the primary factors constraining the growth of the worldwide oncology drug market.
Global Oncology Drugs Market By Segmentation
Oncology market is segmented by Product Type, Cancer Type, End-User and Region.
On the basis of Product Type, the oncology drug market is segmented into Cytotoxic drugs, Targeted drugs and Hormonal drugs. On the basis of Cancer Type, the target market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Bladder Cancer, and Others. Based on End User the market is segmented into Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies.
Regional Insights:
On region the oncology drug market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America has the greatest market for oncology drugs, followed by Europe because of new drug research, government incentives, and developed healthcare infrastructure. Also, Asia-Pacific region is predicted to have a strong growth rate in the oncology drug market in the next years because of the rising prevalence of cancer cases, the increased usage of tobacco products, and the region's ageing population.
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2029 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2029 |
|
Market Segmentation |
By Product Type - Cytotoxic drugs, Targeted drugs, and Hormonal drugs. By Cancer Type – Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Blood Cancer, Bladder Cancer, and Others. By End User – Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies. |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global oncology drug market report based on Product Type, Cancer Type, End User and Region.
Oncology Drug Market, By Region:
- North America
- U.S.
- Canada
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- U.S.
Global Oncology Drugs Market By Key Players
The key players operating in the oncology drug market includes the prominent player operating in the global cancer therapy market includes Key players in the global oncology drugs market includes, Hoffmann-La Roche Ltd., Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., and Bayer AG.
Global Oncology Drugs Market By Company Profile
- Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Celgene Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
“*” marked represents similar segmentation in other categories in the respective section
Global Oncology Drugs Market By Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Preview
- Executive Summary
- Key Findings—Global Outlook for Oncology Drug Strategies
- Key Questions this Study will Answer
- Market Snippet, By Product Type
- Market Snippet, By Cancer Type
- Market Snippet, By End-User
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Market Segmentation, By Product Type, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Cytotoxic Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Targeted Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Hormonal Drugs
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, By Cancer Type, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Lung Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Breast Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Colorectal Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Prostate Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Blood Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Bladder Cancer
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Market Segmentation, By End-User, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Online Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Retail Pharmacies
- Overview
- Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global Market, By Region, 2020 – 2030, (US$ Bn)
- Overview
- Market Value and Forecast (US$ Bn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Bn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Cancer Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Bn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Cancer Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Bn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Cancer Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Bn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Cancer Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Bn), By Product Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Cancer Type, 2020 – 2030
- Market Size and Forecast (US$ Bn), By End-User, 2020 – 2030
- Market Size and Forecast (US$ Bn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Hoffmann-La Roche Ltd.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Celgene Corporation
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Johnson & Johnson
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bristol-Myers Squibb Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Eli Lilly and Company
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- AbbVie Inc.
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Bayer AG
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- The Last Word
- Future Impact
- About Us
- Contact
FAQs
The global oncology drug market is segmented based on Product Type, Cancer Type, End User & Region.
Technological advancements, rising incidence of various types of malignancies, increased demand for R&D activities in cancer, and growing concerns about high cancer-related death rates.
North America has the greatest market for oncology drugs, followed by Europe & also Asia-Pacific region.
Key players in this market are Hoffmann-La Roche Ltd., Novartis International AG, Celgene Corporation, Johnson & Johnson, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, AbbVie Inc., and Bayer AG.